This company has been acquired
TCR2 Therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for TCR2 Therapeutics.
Key information
-0.2%
Earnings growth rate
25.3%
EPS growth rate
| Biotechs earnings growth | 28.8% |
| Revenue growth rate | 74.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 02 Jun 2023 |
Recent future growth updates
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08
Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 13 | -235 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -136 | N/A | N/A | 2 |
| 12/31/2023 | N/A | -139 | N/A | N/A | 3 |
| 3/31/2023 | N/A | -163 | -124 | -110 | N/A |
| 12/31/2022 | N/A | -152 | -117 | -101 | N/A |
| 9/30/2022 | N/A | -119 | -120 | -100 | N/A |
| 6/30/2022 | N/A | -115 | -111 | -93 | N/A |
| 3/31/2022 | N/A | -107 | -101 | -89 | N/A |
| 12/31/2021 | N/A | -100 | -93 | -82 | N/A |
| 9/30/2021 | N/A | -91 | -81 | -72 | N/A |
| 6/30/2021 | N/A | -81 | -72 | -63 | N/A |
| 3/31/2021 | N/A | -73 | -72 | -64 | N/A |
| 12/31/2020 | N/A | -67 | -64 | -57 | N/A |
| 9/30/2020 | N/A | -61 | -57 | -54 | N/A |
| 6/30/2020 | N/A | -58 | -57 | -53 | N/A |
| 3/31/2020 | N/A | -53 | -51 | -47 | N/A |
| 12/31/2019 | N/A | -97 | -45 | -41 | N/A |
| 9/30/2019 | N/A | -96 | -41 | -37 | N/A |
| 6/30/2019 | N/A | -100 | -33 | -32 | N/A |
| 3/31/2019 | N/A | -107 | -27 | -27 | N/A |
| 12/31/2018 | N/A | -62 | -20 | -19 | N/A |
| 9/30/2018 | N/A | -55 | -18 | -17 | N/A |
| 12/31/2017 | N/A | -15 | -12 | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TCRR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TCRR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TCRR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TCRR is forecast to have no revenue next year.
High Growth Revenue: TCRR is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TCRR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/03 16:15 |
| End of Day Share Price | 2023/05/31 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TCR2 Therapeutics Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Clarence Powell | BMO Capital Markets Equity Research |
| Guyn Kim | BMO Capital Markets Equity Research |
| Charles Butler | D. Boral Capital LLC. |